Vanguard Group
AVDL

Vanguard Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Vanguard Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$126M Buy
5,864,781
+258,499
+5% +$5.02M ﹤0.01% 1770
2025
Q3 		$85.6M Buy
5,606,282
+42,023
+0.8% +$547K ﹤0.01% 1925
2025
Q2 		$49.2M Buy
5,564,259
+1,659,609
+43% +$14.6M ﹤0.01% 2128
2025
Q1 		$30.6M Sell
3,904,650
-48,597
-1% -$407K ﹤0.01% 2313
2024
Q4 		$41.5M Buy
3,953,247
+90,147
+2% +$1.09M ﹤0.01% 2245
2024
Q3 		$50.7M Buy
3,863,100
+171,737
+5% +$2.62M ﹤0.01% 2175
2024
Q2 		$51.9M Buy
+3,691,363
New +$60.2M ﹤0.01% 2129

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.22% 1-Year Est. Return

Vanguard Group's AVDL Position: Q4 2025 in Review

Vanguard Group increased its Avadel Pharmaceuticals (AVDL) stake by 4.6% in Q4 2025, buying an estimated $5.02M and bringing the position to 5,864,781 shares worth $126M. The position accounts for ﹤0.01% of the portfolio, ranked #1770.

Vanguard Group first reported a position in AVDL in Q2 2024 and has held it in 7 quarters since. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Vanguard Group held 5,864,781 shares of Avadel Pharmaceuticals worth $126M as of Q4 2025.
  • Vanguard Group bought 258,499 Avadel Pharmaceuticals shares in Q4 2025, an estimated $5.02M.
  • Avadel Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1770 holding.
  • Vanguard Group first reported a position in Avadel Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.